Fig. 2From: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control studyKaplan–Meier estimates of (a) progression-free and (b) overall survival and cumulative incidence estimates of (c) locoregional failure and (d) distant metastasis by assigned treatment. HR, hazard ratio; CCRT, Concurrent ChemoradiotherapyBack to article page